ESR1 and breast cancer: These signatures included PAM50, a 50‐gene signature that was previously reported to be a better prognostic tool for ER+ breast cancers on endocrine therapy than clinical factors, such as histopathological classification and tumor grade (Nielsen et al, 2010).